BJV, based on five major technology platforms, has developed a number of blockbuster APIs such as semaglutide and liraglutide. Meanwhile, it has formed a complete product layout in cosmetic medicines, anti-viral peptide drugs and vaccines, recombinant collagen raw materials to drugs and medical devices.

What's more, in terms of medical beauty raw materials, we have established an exosome production, separation and purification workshop, and started to develop finished products using exosomes as raw materials. Animal experiments on related products are underway.

In term of generic drugs and new drug projects, BJV have obtained great development of targeted peptide (PDC) projects, benchmarking against ADC drugs. With the help of AI technology to assist in new drug development, BJV has succeeded in transferring technologies to large domestic and foreign pharmaceutical companies.

Early this year, we obtained the Shenzhen Specialized and New Enterprise Certification and became one of the "Little Giant" enterprises.

With more than 20 years of experience of R&D and GMP production, BJV has become a powerful enterprise in cosmetic and pharmaceutical industry.